89 related articles for article (PubMed ID: 8649823)
1. A role for activated p21 ras in inhibition/regulation of platelet-derived growth factor (PDGF) type-beta receptor activation.
Zubiaur M; Forman LW; Stice LL; Faller DV
Oncogene; 1996 Mar; 12(6):1213-22. PubMed ID: 8649823
[TBL] [Abstract][Full Text] [Related]
2. Desensitization of the PDGFbeta receptor by modulation of the cytoskeleton: the role of p21(Ras) and Rho family GTPases.
Stice LL; Forman LW; Hahn CS; Faller DV
Exp Cell Res; 2002 Apr; 275(1):17-30. PubMed ID: 11925102
[TBL] [Abstract][Full Text] [Related]
3. The PDGF receptor alpha subunit activates p21ras and triggers DNA synthesis without interacting with rasGAP.
Bazenet CE; Kazlauskas A
Oncogene; 1994 Feb; 9(2):517-25. PubMed ID: 8290262
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
[TBL] [Abstract][Full Text] [Related]
5. Requirement of phosphatidylinositol-3 kinase for activation of JNK/SAPKs by PDGF.
Lopez-Ilasaca M; Li W; Uren A; Yu JC; Kazlauskas A; Gutkind JS; Heidaran MA
Biochem Biophys Res Commun; 1997 Mar; 232(2):273-7. PubMed ID: 9125162
[TBL] [Abstract][Full Text] [Related]
6. Requirement of phospholipase C gamma, the tyrosine phosphatase Syp and the adaptor proteins Shc and Nck for PDGF-induced DNA synthesis: evidence for the existence of Ras-dependent and Ras-independent pathways.
Roche S; McGlade J; Jones M; Gish GD; Pawson T; Courtneidge SA
EMBO J; 1996 Sep; 15(18):4940-8. PubMed ID: 8890167
[TBL] [Abstract][Full Text] [Related]
7. Increased mitogenicity of an alphabeta heterodimeric PDGF receptor complex correlates with lack of RasGAP binding.
Ekman S; Thuresson ER; Heldin CH; Rönnstrand L
Oncogene; 1999 Apr; 18(15):2481-8. PubMed ID: 10229199
[TBL] [Abstract][Full Text] [Related]
8. Caveolin is an inhibitor of platelet-derived growth factor receptor signaling.
Yamamoto M; Toya Y; Jensen RA; Ishikawa Y
Exp Cell Res; 1999 Mar; 247(2):380-8. PubMed ID: 10066366
[TBL] [Abstract][Full Text] [Related]
9. Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity.
Wang YZ; Wharton W; Garcia R; Kraker A; Jove R; Pledger WJ
Oncogene; 2000 Apr; 19(17):2075-85. PubMed ID: 10815799
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
Shawver LK; Schwartz DP; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs JS; Tang C; Ullrich A; Berens ME; Hersh E; McMahon G; Hirth KP; Powell TJ
Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796
[TBL] [Abstract][Full Text] [Related]
11. STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation.
Sachsenmaier C; Sadowski HB; Cooper JA
Oncogene; 1999 Jun; 18(24):3583-92. PubMed ID: 10380880
[TBL] [Abstract][Full Text] [Related]
12. Detection of activated platelet-derived growth factor receptors in human meningioma.
Shamah SM; Alberta JA; Giannobile WV; Guha A; Kwon YK; Carroll RS; Black PM; Stiles CD
Cancer Res; 1997 Sep; 57(18):4141-7. PubMed ID: 9307305
[TBL] [Abstract][Full Text] [Related]
13. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
[TBL] [Abstract][Full Text] [Related]
14. A-Raf associates with and regulates platelet-derived growth factor receptor signalling.
Mahon ES; Hawrysh AD; Chagpar RB; Johnson LM; Anderson DH
Cell Signal; 2005 Jul; 17(7):857-68. PubMed ID: 15763428
[TBL] [Abstract][Full Text] [Related]
15. Pool of ligand-bound platelet-derived growth factor beta-receptors remain activated and tyrosine phosphorylated after internalization.
Sorkin A; Eriksson A; Heldin CH; Westermark B; Claesson-Welsh L
J Cell Physiol; 1993 Aug; 156(2):373-82. PubMed ID: 7688373
[TBL] [Abstract][Full Text] [Related]
16. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes.
Gotzmann J; Fischer AN; Zojer M; Mikula M; Proell V; Huber H; Jechlinger M; Waerner T; Weith A; Beug H; Mikulits W
Oncogene; 2006 May; 25(22):3170-85. PubMed ID: 16607286
[TBL] [Abstract][Full Text] [Related]
17. Modulation of platelet-derived growth factor receptor function in BP3T3, a chemically transformed BALB/c-3T3 cell line.
Grundy P; Bishayee S; Disa S; Scher CD
Cancer Res; 1989 Jul; 49(13):3581-6. PubMed ID: 2543499
[TBL] [Abstract][Full Text] [Related]
18. Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells.
Li W; Michieli P; Alimandi M; Lorenzi MV; Wu Y; Wang LH; Heidaran MA; Pierce JH
Oncogene; 1996 Aug; 13(4):731-7. PubMed ID: 8761294
[TBL] [Abstract][Full Text] [Related]
19. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.
Dahring TK; Lu GH; Hamby JM; Batley BL; Kraker AJ; Panek RL
J Pharmacol Exp Ther; 1997 Jun; 281(3):1446-56. PubMed ID: 9190882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
